Comparative Pharmacology
Head-to-head clinical analysis: ANGIOMAX RTU versus HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIOMAX RTU versus HEPARIN SODIUM 10 000 UNITS AND DEXTROSE 5 IN PLASTIC CONTAINER.
ANGIOMAX RTU vs HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, blocking its interaction with substrates (fibrinogen, factor V, VIII, XIII, and protein C).
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, thereby preventing thrombus formation and propagation.
1 mg/kg intravenous bolus, followed by 0.15 mg/kg/min continuous intravenous infusion for up to 4 hours during percutaneous coronary intervention (PCI). For patients with heparin-induced thrombocytopenia (HIT) undergoing PCI, bolus 0.75 mg/kg, then 1.75 mg/kg/hour infusion for 4 hours.
IV: Initial bolus of 5000 units followed by continuous infusion at 1300 units/hour, adjusted based on aPTT. Typical infusion range 1000-2000 units/hour.
None Documented
None Documented
The terminal elimination half-life of bivalirudin is approximately 25 minutes in patients with normal renal function. In patients with moderate to severe renal impairment, the half-life is prolonged (e.g., up to 1 hour in patients with creatinine clearance <30 mL/min, and up to 3-4 hours in dialysis-dependent patients). This is clinically relevant for dosing adjustments and monitoring of anticoagulation.
30-60 minutes at therapeutic doses, dose-dependent (e.g., 100 U/kg yields t½ ~56 min; 400 U/kg yields ~152 min). At lower doses (e.g., 25 U/kg), t½ is ~30 min. Prolonged in hepatic or renal impairment.
Bivalirudin is cleared by a combination of renal elimination (approximately 20% unchanged in urine) and proteolytic cleavage (hepatic metabolism and other proteases). Renal clearance accounts for about 20% of total clearance. Fecal excretion is negligible (<1%).
Primarily renal; metabolism by hepatic and reticuloendothelial system desulfation yields uroheparin, which is excreted in urine. Unchanged heparin is also excreted renally, with elimination proportional to dose and molecular weight. Biliary/fecal excretion is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant